髋部骨折手术前抗血栓治疗与输血及死亡风险:丹麦全国队列研究
该丹麦全国队列研究纳入2005-2016年74,791例≥65岁髋部骨折手术患者,评估术前抗血栓治疗与术后7天内输血及30天死亡的关系。结果显示,术前使用口服抗凝药与输血或死亡风险无显著关联,而抗血小板药物可能增加输血和死亡风险。
要点
- 术前使用NOAC与输血风险轻度增加相关(aRR 1.07,95%CI 1.01-1.14),但死亡率无显著差异(aHR 0.88,95%CI 0.75-1.03)。
- 术前使用VKA未增加输血或死亡风险。
- 术前使用抗血小板药物与输血风险(aRR 1.15,95%CI 1.12-1.18)和30天死亡风险(aHR 1.18,95%CI 1.14-1.23)增加相关。
核心结论
- 在观察性研究中,术前NOAC或VKA治疗与髋部骨折患者术后30天死亡风险增加无关。
- NOAC与输血风险轻度增加相关。
- 术前使用抗血小板药物与输血和死亡风险增加相关。
研究设计与样本
- 基于丹麦多学科髋部骨折登记处的全国性队列研究,纳入2005-2016年间74,791例年龄≥65岁的髋部骨折手术患者。
- 暴露为入院时使用非维生素K拮抗剂口服抗凝药(NOAC)、维生素K拮抗剂(VKA)或抗血小板药物。
- 结局为术后7天内输血和30天内死亡。
主要发现
- 45.3%的患者接受输血,10.6%死亡。
- 当前使用NOAC与非使用者相比,输血风险轻度增加(aRR 1.07,95%CI 1.01-1.14),但死亡风险相似(aHR 0.88,95%CI 0.75-1.03)。
- 限制于手术延迟<24小时的患者,上述模式保持不变。
- VKA使用者未增加输血或死亡风险。
- 抗血小板药物使用者与非使用者相比,输血风险(aRR 1.15,95%CI 1.12-1.18)和30天死亡风险(aHR 1.18,95%CI 1.14-1.23)增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hip fracture surgery is associated with high risk of bleeding and mortality. The patients often have cardiovascular comorbidity, which requires antithrombotic treatment. This study found that preoperative use of oral anticoagulants was not associated with transfusion or mortality following hip fracture surgery, whereas increased risk may exist for antiplatelet drugs. INTRODUCTION: Hip fracture surgery is associated with high bleeding risk and mortality; however, data on operative outcomes of hip fracture patients admitted while on antithrombotic therapy is sparse. We examined if preoperative antithrombotic treatment was associated with increased use of blood transfusion and 30-day mortality following hip fracture surgery. METHODS: Using data from the Danish Multidisciplinary Hip Fracture Registry, we identified 74,791 hip fracture surgery patients aged ≥ 65 years during 2005-2016. Exposure was treatment with non-vitamin K antagonist oral anticoagulant (NOAC), vitamin K antagonists (VKA), or antiplatelet drugs at admission for hip fracture. Outcome was blood transfusion within 7 days postsurgery and death within 30 days. RESULTS: A 45.3% of patients received blood transfusion and 10.6% died. Current NOAC use was associated with slightly increased risk of transfusion (adjusted relative risk (aRR) 1.07, 95% confidence interval (CI) 1.01-1.14), but similar mortality risk (adjusted hazard ratio (aHR) 0.88, 95% CI 0.75-1.03) compared with non-users. The pattern remained when restricting to patients with short surgical delay (< 24 h). VKA users did not have increased risk of transfusion or mortality. The risks of transfusion (aRR 1.15 95% CI 1.12-1.18) and 30-day mortality (aHR 1.18 95% CI 1.14-1.23) were increased among antiplatelet users compared with non-users. CONCLUSIONS: In an observational setting, neither preoperative NOAC nor VKA treatments were associated with increased risk of 30-day postoperative mortality among hip fracture patients. NOAC was associated with slightly increased risk of transfusion. Preoperative use of antiplatelet drugs was associated with increased risk of transfusion and mortality.
引用
- Daugaard C, Pedersen AB, Kristensen NR, et al. Preoperative antithrombotic therapy and risk of blood transfusion and mortality following hip fracture surgery: a Danish nationwide cohort study. Osteoporos Int. 2018. PMID: 30498889. doi:10.1007/s00198-018-4786-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。